Westfield, IN, United States of America

Natalia Bogatcheva

This inventor holds 2 USPTO granted patents and 1 published patent application. Top assignees: Indiana University, The United States Government as Represented by the Department of Veterans Affairs. Active years: 2018-2021.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Natalia Bogatcheva. Retrieved from https://idiyas.com/inventor/natalia-bogatcheva

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 2 

% Patents Active = 100.0

Average Co-Inventor Count = 2.4

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2018-2021

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Innovations by Inventor Natalia Bogatcheva

Introduction

Natalia Bogatcheva is a prominent inventor based in Westfield, Indiana, known for her significant contributions to medical research and innovation. She holds 2 patents that focus on groundbreaking treatments for viral infections and lung injuries. Her work has the potential to improve therapeutic strategies for patients suffering from severe respiratory conditions.

Latest Patents

One of her latest patents is titled "Emapii neutralizing antibody limits influenza A virus (IAV)-induced lung injury." This invention addresses the detrimental effects of EMAPII, a protein that activates monocytes and endothelial cells, leading to apoptosis in these cells. The patent outlines compositions and methods for treating or preventing apoptosis induced by EMAPII, particularly in the context of Influenza A virus infections. The invention aims to mitigate weight loss, lung edema, and impairment of blood oxygenation associated with IAV infections. Additionally, it proposes anti-EMAPII therapy as a complementary treatment strategy alongside existing antiviral and anti-inflammatory approaches.

Another significant patent is focused on the "Use of ASC and ASC-CM to treat ARDS, SARS, and MERS." This patent reveals that the systemic administration of ASC conditioned media can reduce lung injury caused by LPS by inhibiting epithelial permeability and the inflammatory response. The findings suggest that ASC can be retained in the lungs for an extended period, providing a promising avenue for optimizing cell-based therapies for Acute Respiratory Distress Syndrome (ARDS) and other respiratory infections.

Career Highlights

Natalia has worked with notable institutions, including Indiana University and the United States Government as represented by the Department of Veterans Affairs. Her research has been instrumental in advancing the understanding of lung injuries and developing innovative treatment methods.

Collaborations

Throughout her career, Natalia has collaborated with esteemed colleagues such as Keith Leonard March and Matthias Alexander Clauss. These partnerships have contributed to her success in the field of medical research and innovation.

Conclusion

Natalia Bogatcheva's work exemplifies the impact of innovative research on healthcare. Her patents not only address critical medical challenges but also pave the way for future advancements in treatment strategies. Her contributions are invaluable to the field of medical science.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…